Samsung Bioepis and ATLATL Enter MoU to Advance Early-Stage Biotech Innovation Across Asia-Pacific
Samsung Bioepis Co., Ltd. has entered into a strategic collaboration with ATLATL Innovation Center to strengthen early-stage biotechnology innovation across the Asia-Pacific region. The two organizations announced the signing of a Memorandum of Understanding (MoU) focused on establishing an open innovation framework designed to identify, nurture, and accelerate promising biotech startups and cutting-edge scientific technologies.
This partnership reflects a broader shift within the global biopharmaceutical industry, where collaboration and external innovation are increasingly viewed as essential drivers of drug discovery and development. Rather than relying solely on internal research pipelines, companies are actively seeking partnerships with academic institutions, startups, and innovation hubs to access novel ideas and emerging technologies. Through this collaboration, Samsung Bioepis aims to expand its innovation ecosystem and tap into ATLATL’s extensive regional network, which spans key biotech hubs across Asia-Pacific.
ATLATL has positioned itself as a major player in the life sciences innovation landscape by providing integrated support for early-stage research and development. Its ecosystem connects scientific discovery with the infrastructure, funding, and expertise required to translate ideas into viable therapeutic solutions. By partnering with ATLATL, Samsung Bioepis gains access to a dynamic pipeline of early-stage opportunities, enabling the company to identify breakthrough innovations at an earlier stage and potentially accelerate their path toward clinical and commercial success.
Min Jeong Seo, Vice President and Leader of the Open Innovation Team at Samsung Bioepis, emphasized the growing importance of external collaboration in modern drug development. She noted that innovation today is no longer confined within the walls of a single organization. Instead, it is driven by interconnected ecosystems that bring together diverse expertise and perspectives. According to Seo, fostering early-stage technologies and supporting emerging biotech companies is critical not only for advancing individual programs but also for cultivating a broader, more resilient innovation landscape.
She further highlighted that ATLATL’s position as one of the largest biotech incubation platforms in the Asia-Pacific region makes it an ideal partner. Its ability to connect startups with state-of-the-art facilities, mentorship, and industry expertise creates an environment where scientific ideas can evolve into tangible medical solutions. Through this partnership, Samsung Bioepis aims to play an active role in bridging the gap between early discovery and real-world application, ultimately contributing to the development of new therapies that address unmet medical needs.
From ATLATL’s perspective, the collaboration represents an opportunity to further its mission of enabling the translation of early-stage science into impactful healthcare solutions. Dr. PC Zhu, founder and CEO of ATLATL, underscored the organization’s role in connecting innovation with execution. He explained that while many groundbreaking ideas emerge in academic and startup settings, they often face significant challenges in scaling up and navigating the complexities of drug development. ATLATL addresses these challenges by providing a comprehensive support system that includes laboratory infrastructure, technical expertise, and strategic guidance.
Dr. Zhu expressed confidence that the partnership with Samsung Bioepis will enhance these efforts by bringing additional industry insight and global development capabilities into the ecosystem. Together, the two organizations aim to accelerate the progression of high-potential technologies, ensuring that promising discoveries can move more efficiently from the laboratory to clinical development and, ultimately, to patients.
A key component of the collaboration is the planned launch of the Innovation Prize, an open innovation initiative designed to identify and support outstanding early-stage biotech companies. This program will serve as a platform for emerging innovators to showcase their technologies and gain access to resources that are often difficult to secure in the early phases of development. Selected participants will have the opportunity to reside within ATLATL’s incubation centers, where they can leverage world-class facilities and benefit from close collaboration with experienced scientists and industry professionals.
The Innovation Prize is expected to play a pivotal role in fostering entrepreneurship and encouraging the development of novel therapeutic approaches. By providing both financial and operational support, the program aims to reduce barriers to innovation and enable startups to focus on advancing their scientific breakthroughs. For Samsung Bioepis, the initiative represents a strategic avenue to engage directly with emerging innovators and explore potential partnerships or investments that align with its long-term growth objectives.
This collaboration also highlights the increasing importance of the Asia-Pacific region in the global biotechnology landscape. Over the past decade, the region has seen rapid growth in research capabilities, investment, and startup activity, making it a fertile ground for innovation. Countries across Asia-Pacific are investing heavily in life sciences infrastructure and talent development, creating a vibrant ecosystem that is attracting attention from global pharmaceutical and biotechnology companies.
By aligning with ATLATL, Samsung Bioepis is positioning itself to capitalize on these regional dynamics and strengthen its presence in one of the fastest-growing biotech markets in the world. The partnership not only enhances the company’s ability to access new technologies but also reinforces its commitment to supporting the next generation of biotech innovators.
In a broader sense, the agreement underscores a fundamental evolution in how the biopharmaceutical industry approaches innovation. Open innovation models, which emphasize collaboration, resource sharing, and ecosystem development, are becoming increasingly central to the discovery and development of new medicines. By embracing this approach, companies like Samsung Bioepis are better equipped to navigate the complexities of modern drug development and respond to the growing demand for innovative therapies.
In conclusion, the MoU between Samsung Bioepis and ATLATL Innovation Center represents a forward-looking initiative aimed at accelerating early-stage biotech innovation in the Asia-Pacific region. Through their combined strengths, the two organizations are creating a platform that supports the discovery, development, and translation of breakthrough technologies. As the partnership evolves, it has the potential to drive meaningful advancements in healthcare and bring new treatment options to patients worldwide, while also strengthening the broader innovation ecosystem that underpins the future of biotechnology.
About Samsung Bioepis Co., Ltd.
Established in 2012, Samsung Bioepis is a biopharmaceutical company committed to realizing healthcare that is accessible to everyone. Through innovations in product development and a firm commitment to quality, Samsung Bioepis aims to become the world’s leading biopharmaceutical company. As a wholly owned subsidiary of Samsung Epis Holdings, Samsung Bioepis continues to advance a broad pipeline of biologic candidates that cover a spectrum of therapeutic areas, including immunology, oncology, ophthalmology, hematology, nephrology, endocrinology. For more information, please visit www.samsungbioepis.com and follow us on LinkedIn and X.
About ATLATL
As a global innovation platform for life science research and development, ATLATL has established research centers in Beijing, Shanghai, Shenzhen, Singapore, Hong Kong, and other strategic locations.
ATLATL provides clients with comprehensive research and development services covering various stages, including in vitro drug screening, in vivo disease model establishment, and efficacy evaluation. ATLATL also supports key applications such as large molecule, small molecule, nucleic acid drugs, gene and cell therapy, drug delivery, as well as cutting-edge fields such as multi-omics, gene editing, organoids, and organ-on-a-chip. Additionally, ATLATL provides an outstanding experimental environment and professional operational management for scientific researchers.
Through in-depth cooperation with leading global enterprises and research institutions, ATLATL continuously integrates research and development resources and promotes the sharing of new technologies. With advanced systematic research and development models, ATLATL accelerates the engineering process of life sciences, enabling scientific research results to be rapidly and efficiently translated into clinical practice, and contributing to life science innovation and public health on a global level.
Source Link:https://www.businesswire.com/
